300

StakingFarm Introduces a Strategic Blueprint for Crypto Staking Success Amid Market Volatility

Source Node:
Time Stamp: March 20, 2024 8:47 AM - Modified On: March 20, 2024 - Published By:
Source Cluster:
Republished By Plato

  London, England – In an era defined by the digital revolution and the emergence of cryptocurrency as a formidable asset class, StakingFarm is proud to announce its advanced approach to crypto staking, designed to navigate the tumultuous waters of market volatility. This strategic blueprint is not merely a response to the fluctuations inherent in the crypto market; it is a comprehensive guide for investors seeking to maximize their earnings through staking crypto, transforming volatility from a challenge into an opportunity. "Volatility in the crypto market is not a barrier;

Analyzing Token Sale Models

Source Node:
Time Stamp: February 20, 2024 1:29 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

Note: I mention the names of various projects below only to compare and contrast their token sale mechanisms; this should NOT be taken as an endorsement or criticism of any specific project as a whole. It's entirely possible for any given project to be total trash as a whole and yet still have an awesome token sale model. The last few months have seen an increasing amount of innovation in token sale models. Two years ago, the space was simple: there were capped sales, which sold a fixed number of

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Source Node:
Time Stamp: December 7, 2023 3:23 PM - Modified On: December 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, D.C, December 7, 2023 — Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW). Under this MOU, both Curio and Deep Isolation will mutually collaborate and exchange critical information for the use of Deep Isolation’s Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for the isolation and management of HLW

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating